New Drugs for Tuberculosis: Current Status and Future Prospects
Authors:
- Richard J. O'BRienRORichard J. O'BRien
- Mel SpigelmanMSMel Spigelman
- 1 June 2005
- journal article
- review article
- Published by Elsevier in Clinics in Chest Medicine
- Vol. 26 (2) , 327-340
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- The European research effort for HIV/AIDS, malaria and tuberculosisVaccine, 2003
- The Growing Burden of TuberculosisArchives of internal medicine (1960), 2003
- Tuberculosis trends in the United States, 1992–2001Tuberculosis, 2003
- Worldwide Incidence of Multidrug‐Resistant TuberculosisThe Journal of Infectious Diseases, 2002
- Evolution of WHO policies for tuberculosis control, 1948–2001The Lancet, 2002
- The Need for New Drugs against TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Targeted Tuberculin Testing and Treatment of Latent Tuberculosis InfectionAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Critical assessment of smear-positive pulmonary tuberculosis patients after chemotherapy under the district tuberculosis programmeTubercle and Lung Disease, 1993
- Controlled Trial of 2, 4, and 6 Months of Pyrazinamide in 6-Month, Three-Times-Weekly Regimens for Smear-positive Pulmonary Tuberculosis, Including an Assessment of a Combined Preparation of Isoniazid, Rifampin, and Pyrazinamide: Results at 30 MonthsAmerican Review of Respiratory Disease, 1991
- Rifabutin (Ansamycin LM 427): A New Rifamycin-S Derivative for the Treatment of Mycobacterial DiseasesClinical Infectious Diseases, 1987